Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations
Due to groundbreaking developments and continuous progress, the treatment of stage IV non-small cell lung cancer (NSCLC) has become an exciting but increasingly challenging task. This applies in particular to the subgroup of NSCLC with oncogenic driver alterations. While the treatment of epidermal g...
Main Authors: | David König, Sacha I. Rothschild |
---|---|
Format: | Article |
Language: | English |
Published: |
THE HEALTHBOOK COMPANY LTD.
2020-10-01
|
Series: | healthbook TIMES. Oncology Hematology |
Online Access: | https://healthbook-times.scholasticahq.com/article/24805-molecular-diagnostic-and-precision-medicine-in-non-small-cell-lung-cancer-an-update-on-the-treatment-of-the-most-important-actionable-oncogenic-drive.pdf |
Similar Items
-
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
by: David König, et al.
Published: (2021-02-01) -
Oncogenic driver mutations in Vietnamese patients with lung adenocarcinoma
by: Linh Dieu Vuong, et al.
Published: (2023-08-01) -
Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations
by: Fabio Pastorino, et al.
Published: (2022-09-01) -
Oncogenic drivers and development
by: Cruz Hernandez, D, et al.
Published: (2019) -
Epigenetic therapy in lung cancer – role of microRNAs
by: Sacha I Rothschild
Published: (2013-06-01)